• Skip to primary navigation
  • Skip to main content
  • Skip to primary sidebar
  • Skip to footer
  • Advertise
  • Subscribe

MassDevice

The Medical Device Business Journal — Medical Device News & Articles | MassDevice

  • Latest News
  • Technologies
    • Artificial Intelligence (AI)
    • Cardiovascular
    • Orthopedics
    • Neurological
    • Diabetes
    • Surgical Robotics
  • Business & Finance
    • Wall Street Beat
    • Earnings Reports
    • Funding Roundup
    • Mergers & Acquisitions
    • Initial Public Offering (IPO)
    • Legal News
    • Personnel Moves
    • Medtech 100 Stock Index
  • Regulatory & Compliance
    • Food & Drug Administration (FDA)
    • Recalls
    • 510(k)
    • Pre-Market Approval (PMA)
    • MDSAP
    • Clinical Trials
  • Special Content
    • Special Reports
    • In-Depth Coverage
    • DeviceTalks
  • Podcasts
    • MassDevice Fast Five
    • DeviceTalks Weekly
    • OEM Talks
      • AbbottTalks
      • Boston ScientificTalks
      • DeviceTalks AI
      • IntuitiveTalks
      • MedtechWOMEN Talks
      • MedtronicTalks
      • Neuro Innovation Talks
      • Ortho Innovation Talks
      • Structural Heart Talks
      • StrykerTalks
  • Resources
    • About MassDevice
    • DeviceTalks
    • Newsletter Signup
    • Leadership in Medtech
    • Manufacturers & Suppliers Search
    • MedTech100 Index
    • Videos
    • Webinars
    • Whitepapers
    • Voices
Home » NIH: Intensive BP management cuts cardiovascular events, deaths

NIH: Intensive BP management cuts cardiovascular events, deaths

September 11, 2015 By Fink Densford

National Institute of HealthA new study from the National Institute of Health reports that intensive blood pressure management reduces the risk of death and cardiovascular events when compared to a strategy that only lowers systolic blood pressure to standard targets.

The data comes from the initial results of the Institute’s Sprint systolic blood pressure intervention trial, which sought to evaluate the benefits of maintaining a lower target for systolic blood pressure. The study examined patients 50 years and older at risk of heart disease, or who have kidney disease, according to the Institute.

“This study provides potentially lifesaving information that will be useful to health care providers as they consider the best treatment options for some of their patients, particularly those over the age of 50. We are delighted to have achieved this important milestone in the study in advance of the expected closure date for the SPRINT trial and look forward to quickly communicating the results to help inform patient care and the future development of evidence-based clinical guidelines,” National Heart, Lung, and Blood Institute director Dr. Gary Gibbons said in a press release.

The study examined over 9,300 patients recruited from 100 centers across the U.S. and Puerto Rico. It is the largest study of its kind to examine the effect of maintaining systolic blood pressure at lower than currently recommended levels and its effect on cardiovascular and kidney diseases, the NIH said.

Patients in the study were split into 2 groups, differing the the levels of blood pressure control used in each. The 1st group received medications to bring their blood pressure to a target lower than 140 mm Hg, and the other below 120 mm Hg.

Results indicated that maintaining a lower systolic pressure lead to a significant decrease in cardiovascular events and deaths, and the NIH said the results were strong enough to stop the trial in order to quickly disseminate the significant preliminary results.

“Our results provide important evidence that treating blood pressure to a lower goal in older or high-risk patients can be beneficial and yield better health results overall. But patients should talk to their doctor to determine whether this lower goal is best for their individual care,” NHLBI chief of clinical applications and prevention Dr. Lawrence Fine said in prepared remarks.

Filed Under: Cardiovascular, Clinical Trials Tagged With: National Institutes of Health (NIH)

More recent news

  • Imperative Care has positive stroke treatment study results
  • Medtronic enrolls first patient in study for Onyx liquid embolic system
  • Intuitive demonstrates remote telesurgery capabilities with da Vinci 5
  • BD issues voluntary recall on certain Alaris infusion pump modules
  • CVRx announces Medicare win for Barostim therapy

Primary Sidebar

“md
EXPAND YOUR KNOWLEDGE AND STAY CONNECTED
Get the latest med device regulatory, business and technology news.

DeviceTalks Weekly

See More >

MEDTECH 100 Stock INDEX

Medtech 100 logo
Market Summary > Current Price
The MedTech 100 is a financial index calculated using the BIG100 companies covered in Medical Design and Outsourcing.
MDO ad

Footer

MASSDEVICE MEDICAL NETWORK

DeviceTalks
Drug Delivery Business News
Medical Design & Outsourcing
Medical Tubing + Extrusion
Drug Discovery & Development
Pharmaceutical Processing World
MedTech 100 Index
R&D World
Medical Design Sourcing

DeviceTalks Webinars, Podcasts, & Discussions

Attend our Monthly Webinars
Listen to our Weekly Podcasts
Join our DeviceTalks Tuesdays Discussion

MASSDEVICE

Subscribe to MassDevice E-Newsletter
Advertise with us
About
Contact us

Copyright © 2025 · WTWH Media LLC and its licensors. All rights reserved.
The material on this site may not be reproduced, distributed, transmitted, cached or otherwise used, except with the prior written permission of WTWH Media.

Privacy Policy